New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade Construction will begin in fall 2025 with the site expected to be fully operational in 2027 Furthers AbbVie's long-term commitment to the U.S.... Read More

Allergan Aesthetics Celebrates Third Annual JUVÉDERM ® Day with BOGO Gift Cards and $10,000 Sweepstakes Join Allē Today to Take Advantage of Limited-Time Offers, While Supplies Last IRVINE, Calif. , Aug. 6, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announces the return of JUVÉDERM ® Day , Wednesday, August 20 . This year's holiday marks the third annual celebration of aesthetics... Read More

Nine women from across the U.S. share their personal experiences with breast augmentation and reconstruction with Natrelle ® – celebrating confidence, self-expression, and restoration. IRVINE, Calif. , Aug. 5, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is launching its Faces of Natrelle ® campaign – a powerful tribute to resilience and authenticity. The campaign features nine inspiring women... Read More

Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97 , an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $15.423 Billion , an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis Second-Quarter Global... Read More

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ ® ) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 20 1 Key secondary endpoints, including improvements in eyebrows and... Read More

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed statistically significant improvement in progression-free survival vs chemoimmunotherapy Regimen offers an opportunity for patients to take time off treatment, an important step toward improved disease management NORTH CHICAGO, Ill.... Read More

Select Business Owners Will Receive Access to Coaching, Mentorship, and Community During Exclusive 12-Week Virtual "Boostcamp" Additionally, 20 Entrepreneurs Will Each Receive a $20,000 Grant from BOTOX ® Cosmetic IRVINE, Calif. , July 22, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2025 class of entrepreneurs who will participate in The Confidence Project: Empowering Women... Read More

Refresh Advanced OMEGA-3 Lubricant Eye Drops are the first eye drops on the market with omega-3 fatty acids MONTREAL , July 11, 2025 /CNW/ - AbbVie (NYSE: ABBV), announced today the availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada . The new, preservative-free eye drop is designed to provide rapid and long-lasting relief from dry eyes with the inclusion of natural omega-3 oil that helps lock in moisture.... Read More

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NORTH CHICAGO, Ill. and NEW YORK , July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York -based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's... Read More

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseases Proposed acquisition strengthens AbbVie's commitment to transforming the future of patient care with Capstan's innovative tLNP platform... Read More

SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness. If approved, SKINVIVE by JUVÉDERM® will be the first hyaluronic acid injectable treatment option aiming to reduce neck lines. The application for indication expansion is supported by a clinical study that met all primary and secondary endpoints assessing SKINVIVE by... Read More

NORTH CHICAGO, Ill. , June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that... Read More

NORTH CHICAGO, Ill. , June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable August 15, 2025 , to stockholders of record at the close of business on July 15, 2025 . Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index,... Read More

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month 1 Atogepant met the primary endpoint of fewer treatment discontinuations attributed to adverse events versus topiramate, and all six secondary endpoints... Read More

NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed. 1 Results from... Read More

MAVYRET ® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, providers can now treat HCV patients immediately at the time of diagnosis HCV is a curable condition, but patients can often go undiagnosed. 1 If left untreated, people with acute HCV could progress to chronic disease, including... Read More

The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is committed to supporting the migraine community beyond treatment. Migraine affects productivity and career growth—up to 90% of people... Read More

NORTH CHICAGO, Ill. , June 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 . Management will participate in a fireside chat at 10:20 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be... Read More

Chicago -based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill. , May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer through a campaign called "Striking Out Cancer" which starts today when the Chicago Cubs play the Cincinnati Reds. As part of the first... Read More

Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic cell neoplasm (BPDCN). NORTH CHICAGO, Ill. , May 27, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV)... Read More

Following a national competition, AbbVie and SpinUp – the University of Toronto's lab-based, life sciences accelerator – announce Neuropeutics Inc as recipient of first AbbVie Biotech Innovators Award Neuropeutics Inc receives a year of laboratory space and equipment at no cost, as well as access to support and mentorship TORONTO , May 22, 2025 /CNW/ - AbbVie (NYSE: ABBV) in partnership with the University of Toronto's... Read More

EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited treatment options Lung cancer remains the leading cause of cancer-related deaths throughout the world 1 NORTH CHICAGO, Ill. , May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that EMRELIS ™ (telisotuzumab vedotin-tllv) has been... Read More

Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies across neuroscience, immunology and oncology NORTH CHICAGO, Ill. and SAN DIEGO , May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA... Read More

NORTH CHICAGO, Ill. , May 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025 . Management will participate in a fireside chat at 12:00 p.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be... Read More

BOTOX ® Cosmetic Will Provide 250 Entrepreneurs with Access to New Resources and Opportunities and Will Award 20 Grants Worth $20,000 Each to Support Business Goals. By 2030, BOTOX ® Cosmetic Pledges to Empower 50,000 Entrepreneurs, Helping to Close the Confidence Gap. IRVINE, Calif. , May 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced BOTOX ® Cosmetic's continued commitment to... Read More

RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries 2 This marks the ninth approved indication for RINVOQ in the U.S., across rheumatology, gastroenterology, and dermatology 1 NORTH CHICAGO, Ill. , April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV)... Read More

Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46 , an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $13.343 Billion , an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis First-Quarter Global Net... Read More

TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks. If approved, TrenibotE will be the first neurotoxin of its kind available to patients. Submission is supported by data from over 2,100 patients treated with TrenibotE throughout the clinical program. NORTH... Read More

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that RINVOQ achieved the primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and... Read More

NORTH CHICAGO, Ill. , March 31, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that... Read More

Data for ABBV-969, a novel STEAP1/PSMA dual-targeted antibody-drug conjugate (ADC) in Phase 1 for advanced prostate cancer, will be presented in an oral presentation. Data to be presented on ABBV-514, a novel CCR8 targeting antibody, in Phase 1 for non-small cell lung cancer, head and neck cancer and other solid tumors. Other presentations highlight key insights into treatment resistance and biomarker identification based on... Read More

Four expert-led educational events with Allergan Medical Institute (AMI), Science of Aging TM and Allergan Aesthetics (AA) Global Medical Affairs AMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years of MD Codes™, with live injection sessions and fireside chat with world-renowned plastic surgeon Dr. Maurício de Maio Eleven E-Poster data presentations and Meet the Expert sessions... Read More

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Seattle NORTH CHICAGO, Ill. , March 15, 2025... Read More

SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease. 1 MONTREAL , March 4, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were... Read More

NORTH CHICAGO, Ill. , March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025 . Management will participate in a fireside chat at 7:40 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available... Read More

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill. and HØRSHOLM, Denmark , March 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical... Read More

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA) 1 The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission, † were met 1 GCA is an autoimmune disease that causes inflammation of the... Read More

NORTH CHICAGO, Ill. , Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025 . Management will participate in a fireside chat at 8:10 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be... Read More

Richard A. Gonzalez to retire from the board of directors effective July 1, 2025 NORTH CHICAGO, Ill. , Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025 . He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been... Read More

NORTH CHICAGO, Ill. , Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable May 15, 2025 , to stockholders of record at the close of business on April 15, 2025 . Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index,... Read More

Allergan Medical Institute (AMI) Training Centers to offer most comprehensive, training programs accelerating providers' consultative and clinical skills Innovative curriculum will empower providers to deliver outcomes with excellence and support loyal patient relationships IRVINE, Calif. , Feb. 12, 2025 /PRNewswire/ --... Read More

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass. , Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company... Read More

EMBLAVEO TM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies Antimicrobial resistance (AMR) could lead to over 39... Read More

Consumers Can Apply Today for a Chance to be Featured in an Upcoming Campaign by Natrelle ® and Share Their Personal Stories. Natrelle ® is the #1 Selected Breast Implant by Leading U.S. Physicians * Offering the Largest Range of Options For Every Curve, Every Shape, For Every BODY. IRVINE, Calif. , Feb. 6, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced a nationwide open casting call in... Read More

New video content featuring Dr. Caroline Glicksman and Dr. Melinda (Mindy) Haws available now on the LIMITLESS YouTube channel LIMITLESS Leaders' Summit to be held February 5-6, 2025 in Boston , spotlighting engaging speakers, breakout sessions IRVINE, Calif. , Feb. 5, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, is continuing its dedication to the LIMITLESS initiative by expanding the content of its... Read More

Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12 , a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to 2024 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $56.334 Billion , an Increase of 3.7 Percent on a Reported Basis and 4.6 Percent on an Operational Basis Full-Year Global Net... Read More

AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes NORTH CHICAGO, Ill. , Jan. 29, 2025 /PRNewswire/ -- In response to growing demand for personalized, patient-centric aesthetic solutions 1,2 , Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature program, an innovative approach to treatment planning harnessing the power of Allergan Aesthetics'... Read More

New AA (Allergan Aesthetics) Signature Program provides a personalized approach to treatment planning, in combination with Allergan Aesthetics' advanced facial portfolio to address patient needs and treat different areas of the face Expert led Allergan Medical Institute (AMI) symposium will demonstrate how to elevate the patient experience and achieve optimal treatment outcomes using AA Signature program looks The Allergan... Read More

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie. Nimble's... Read More

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO , Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement... Read More

NORTH CHICAGO, Ill. and SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a... Read More

Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) NORTH CHICAGO, Ill. and ROCKVILLE, Md. , Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today... Read More

NORTH CHICAGO, Ill. , Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 . Management will participate in a fireside chat at 10:15 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available... Read More

Get Treated with CoolSculpting ® Elite and Enter for a Chance to Win $10,000* Starting Today, First-Time Users Can Claim $300 Off Their Treatment † IRVINE, Calif. , Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting ® Elite. The celebration is an opportunity for consumers interested in body contouring to reach out to a CoolSculpting ®... Read More

NORTH CHICAGO, Ill. , Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be... Read More

The 2024 Canadian Headache Society (CHS) Migraine Prevention Guideline, which replaces the previous version published in 2012, granted strong recommendations for atogepant in episodic and chronic migraine, and for onabotulinumtoxinA in chronic migraine. 1 The new CHS Migraine Prevention Guideline is based on a comprehensive systematic review and meta-analysis and addresses both episodic and chronic migraine. 1 A strong... Read More

Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where significant unmet needs remain Acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics NORTH CHICAGO,... Read More

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilities NORTH CHICAGO, Ill. , Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part... Read More

Data presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66 th Annual Meeting and... Read More

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26 1 Trial also met its key secondary endpoint, demonstrating statistically significant improvement from baseline in the MDS-UPDRS Part II score at week 26 1 Positive results across all three Phase 3... Read More

New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys CLL is one of the most common leukemias among adults affecting more than 200,000 people in the U.S. 1,2 NORTH CHICAGO, Ill. , Dec. 8, 2024 /PRNewswire/ - - AbbVie announced groundbreaking results today from its latest Emotional Impact Report... Read More

Data presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b /2 EPCORE ® NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide + rituximab (R 2 ) in adult... Read More

NORTH CHICAGO, Ill. , Nov. 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 . Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D., executive vice president, Research & Development and chief scientific officer, will present at... Read More

Seven new e-trainings, all 30 minutes or less, are available starting today through Allergan Medical Institute® (AMI) at AMIOnline.com IRVINE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, launched AMI Business Education, a new addition to the AMI Online learning platform available for free to all Allergan Aesthetics customers. This innovative offering empowers healthcare practitioners, their... Read More

ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with chemotherapy VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the companion diagnostic to identify ovarian... Read More

AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in migraine treatment, is committed to addressing the impact of migraine in the workplace Nearly 40 million Americans are living with migraine, a debilitating neurological disease, and are more likely to call in sick due to symptoms... Read More

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, Ill. , Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an... Read More

Last Year, BOTOX ® Cosmetic Day Set the Record for the Most BOTOX ® Cosmetic Gift Cards Sold in a Single Day 1 This Year, the Excitement Continues with New Offers to Refer a Friend Plus the Best-Selling Buy-One-Get-One (BOGO) Free Gift Card Offer Join Allē Today to Take Advantage of Exclusive Offers IRVINE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the sixth... Read More

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn. , Oct. 31, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell... Read More

Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00 , an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $14.460 Billion , an Increase of 3.8 Percent on a Reported Basis or 4.9 Percent on an Operational Basis Third-Quarter Global Net... Read More

MONTREAL , Oct. 29, 2024 /CNW/ - AbbVie (NYSE: ABBV) announced today that Ontario has listed VRAYLAR ® (cariprazine) on its provincial formulary as a General Benefit . The listing will be effective on October 31, 2024 . This listing is new step towards more equitable access to mental illness medication in Canada . As up to 90% of Canadians with serious mental illness are unemployed 1 , public plan coverage is critical for... Read More

SkinSpirit will make a kick-off donation and offer clients the ability to donate directly to Girls Inc. from November 1 – 15 th IRVINE, Calif. , Oct. 29, 2024 /PRNewswire/ -- In its sixth year of partnership with Girls Inc., Allergan Aesthetics, an AbbVie company, will be joined by SkinSpirit, a premier destination for medical aesthetics and skincare, in their efforts to inspire girls to be strong, smart and bold and explore... Read More

Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience NORTH CHICAGO, Ill. and BOSTON , Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics... Read More

Companies will discover and develop novel targets for the potential treatment of neuropsychiatric conditions New discovery program builds upon nearly two decades of partnership between AbbVie and Gedeon Richter NORTH CHICAGO, Ill. and BUDAPEST, Hungary , Oct. 24, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel... Read More

MONTREAL , Oct. 21, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large B-cell lymphoma (R/R DLBCL) not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular... Read More

The Only Product of Its Kind Approved for Use in Four Aesthetic Indications: Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines, Frown Lines, Crow's Feet Lines, and Now Platysma Bands in Adults 1-5 With this Approval, BOTOX ® Cosmetic is the First and Only Aesthetic Neurotoxin Product to Temporarily Improve the Appearance of Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma... Read More

VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV reported superior improvement in "on" time without troublesome dyskinesia, compared to oral immediate-release carbidopa/levodopa 1 VYALEV allows for personalized dosing based on individual needs, morning, day and night NORTH... Read More

A total of 12 abstracts, including four Best of Cosmetic Abstracts, demonstrate Allergan Aesthetics' commitment to patient outcomes and detailed insights and understanding of key concerns across differentiated patient segments Insightful panel discussion with Dr. Kavita Mariwalla , ASDS President Elect (2026) and double board-certified dermatologist, on impact of social media on patient experience and expectations when... Read More

Live panel discussion at the Girls Inc. Be Bold LeadHERS Summit at Houston Community College with expert women healthcare providers IRVINE, Calif. , Oct. 4, 2024 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company, announces the sixth consecutive year of partnership with Girls Inc. The partnership supports high school and college girls' interest in STEM and mentorship. "In 2023, women made up just 28% of the STEM... Read More

JUVÉDERM ® VOLUMA ® XC is the One and Only Hyaluronic Acid Dermal Filler Indicated to Treat Cheeks, Chin, and Now Moderate to Severe Temple Hollowing 1,2 Only Allergan Aesthetics, the Makers of BOTOX ® Cosmetic (onabotulinumtoxinA), has FDA-Approved Injectables to Treat More Than 90% of the Face 2-8 IRVINE, Calif. , Oct. 2, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national... Read More

NORTH CHICAGO, Ill. , Oct. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that... Read More

Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. Biologics License Application (BLA) submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial (M14-239). Review of the BLA will be conducted under FDA's Oncology Center of Excellence (OCE) Real-Time Oncology Review... Read More

National competition, in collaboration with SpinUp, the University of Toronto's lab-based life sciences accelerator, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Canada One Canadian biotech will receive a year of laboratory space and equipment at no cost, as well as access to support and mentorship Applications will be accepted until January 17, 2025 TORONTO , Sept. 26, 2024 /CNW/ - AbbVie (NYSE:... Read More

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26 Trial also met key secondary endpoint, demonstrating statistically significant improvement from baseline in the MDS-UPDRS Part II score Results from the Phase 3 TEMPO-2 trial, studying tavapadon as a... Read More

New post-hoc analysis demonstrated efficacy of RINVOQ ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of severity in head and neck involvement, with results in skin clearance, itch resolution and impact on quality of life at 16 weeks 1 Atopic dermatitis in the head and neck regions can have a significant impact on the quality of life for patients and is highly prevalent based on... Read More

Help Close the "Confidence Gap" By Backing Your Favorite BOTOX ® Cosmetic Grant Recipients With Women-Led Startups Receiving Less Than Three Percent of Venture Capital Funding 1 , Your Support Can Help Bridge the Gap and Empower Women Entrepreneurs IRVINE, Calif. , Sept. 24, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is proud to announce the next exciting phase of its 2024 BOTOX ® Cosmetic grant... Read More

NORTH CHICAGO, Ill. , Sept. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine (ELAHERE ® ) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant and high-grade serous... Read More

BOTOX ® Cosmetic is the first neurotoxin approved in China for the treatment of masseter muscle prominence (MMP), the largest global market for MMP. Approval supported by well-established safety profile and robust clinical trials demonstrating BOTOX ® Cosmetic is effective in reducing the prominence of the masseter muscle. Allergan Aesthetics intends to develop onabotulinumtoxinA treatment for MMP in additional global... Read More

CONSTELLA is the first and only Health Canada-approved prescription therapy for functional constipation in this patient population Submission is based on positive Phase 3 study data demonstrating linaclotide (72mcg) resulted in increases in frequency of spontaneous bowel movements (SBM) in children and adolescents aged 6 to 17 years MONTREAL , Sept. 10, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that Health Canada has... Read More

Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (ELAHERE®), for high folate receptor-alpha (FRα) expressing platinum-sensitive ovarian cancer (PSOC) (mini-oral presentation). Exploratory patient reported outcomes (PROs) from the Phase 2 LUMINOSITY trial, evaluating telisotuzumab vedotin (Teliso-V), a potential first-in-class c-Met directed... Read More

NORTH CHICAGO, Ill. , Sept. 6, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable November 15, 2024 , to stockholders of record at the close of business on October 15, 2024 . Since the company's inception in 2013, AbbVie has increased its dividend by more than 285 percent. AbbVie is a member of the S&P Dividend... Read More

VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada on April 22, 2022 . Following the positive recommendation from INESSS issued in October 2022 , VRAYLAR completed negotiations at pCPA and has an active letter of intent (LOI). Québec and the federal plans (NIHB, CSC and VAC) have subsequently listed VRAYLAR, for the treatment of schizophrenia, as a result of this completed... Read More

More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016 NORTH CHICAGO, Ill. , Aug. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic, inflammatory diseases as they pursue higher education. Due to the constraints of... Read More

SkinMedica ® , by the makers of BOTOX ® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE ® Technology for deeper hydration IRVINE, Calif. , Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica ®... Read More

TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapy FL is an incurable form of non-Hodgkin's lymphoma (NHL), with about 13,000 estimated cases in Western Europe alone each year 1 NORTH... Read More

MONTREAL , Aug. 15, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that EPKINLY is now listed on the Ontario Health (Cancer Care Ontario) formulary under the NDFP (New Drug Funding Program) and the HCTFP (High Cost Therapy Funding Program) programs 1 and the Régie de l'assurance maladie du Québec (RAMQ) Liste des médicaments - Établissements 2 for the treatment of adult patients with Relapsed or Refractory Diffuse Large... Read More

Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie... Read More

Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM ® Day on August 21, 2024 Members receive an exclusive gift card offer and a chance to win $10,000* IRVINE, Calif. , July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM ® Day on Wednesday, August 21 . After a successful first year, JUVÉDERM ® Day is back with limited time... Read More

The marketing authorization for SKYRIZI ® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induction trial 1 and COMMAND maintenance trial 2 In both trials, SKYRIZI achieved the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including mucosal healing** and histologic... Read More

Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65 , a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0.52 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $14.462 Billion , an Increase of 4.3 Percent on a Reported Basis and 5.6 Percent on an Operational Basis Second-Quarter Global... Read More

Time-limited reimbursement (TLR) recommendation is a new Canada's Drug Agency (CDA) review process whereby a temporary recommendation is issued based on a phase II clinical data assessment, and the final recommendation is contingent upon a future reassessment of additional evidence (i.e., phase III clinical data) 1 . The... Read More

Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission from week 12 through week 52 1 The safety profile of upadacitinib in patients with GCA was generally consistent with that in approved indications 1 NORTH CHICAGO, Ill. , July 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has... Read More

NORTH CHICAGO, Ill. , July 10, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that Roopal Thakkar , M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of executive vice president, research & development and chief scientific officer. In this position, Dr. Thakkar will lead the company's global R&D organization of more than 14,000 team... Read More

NORTH CHICAGO, Ill. , July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that... Read More

As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive Chairman Robert A. Michael Joins AbbVie Board of Directors NORTH CHICAGO, Ill. , July 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that Robert A. Michael has assumed the role of chief executive officer (CEO) and has joined AbbVie's Board of Directors, effective today. As previously announced, Mr. Michael... Read More

If approved, epcoritamab (TEPKINLY ® ) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapy Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study NORTH CHICAGO, Ill. , June 28, 2024... Read More

Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. , June 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease.... Read More

Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and Products, Increasing Affordability of Treatments with Flexible Payment Options IRVINE, Calif. , June 27, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today debuted Allē Payment Plans , powered by... Read More

EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL) Bispecific antibodies are designed to induce targeted cell killing by engaging the immune system FL is considered incurable with current standard of care therapies. Many people living with FL who have relapsed or are refractory to existing... Read More

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manufacturing facilities The CRL does not identify any issues related to the safety, efficacy or labeling of ABBV-951, including the device, and does not request that AbbVie conduct additional efficacy or safety trials related to the... Read More

NORTH CHICAGO, Ill. , June 21, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable August 15, 2024 , to stockholders of record at the close of business on July 15, 2024 . Since the company's inception in 2013, AbbVie has increased its dividend by more than 285 percent. AbbVie is a member of the S&P Dividend... Read More

Ms. Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director NORTH CHICAGO, Ill. , June 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director, effective July 1, 2024 . Ms. Austin succeeds Glenn F. Tilton , who has served as lead independent director since 2013. Mr. Tilton will... Read More

Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI ® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE, 1 and a 52-week maintenance study, COMMAND 2 Data showed that clinical remission, the primary endpoint in both the induction and maintenance studies, was achieved along with endoscopic improvement, a key secondary endpoint 1 , 2 SKYRIZI is the first IL-23... Read More

NORTH CHICAGO, Ill. , June 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024 , to purchase up to 250,000 shares of AbbVie common stock at $165.00 per share in cash (Offer Price). This offer is conditioned on, among other things, the closing price per share of AbbVie's common stock exceeding the Offer Price on the... Read More

Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. and BEIJING , June 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and FutureGen Biopharmaceutical ( Beijing ) Co., Ltd. today announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.... Read More

For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence Gap IRVINE, Calif. , June 11, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) revealed this year's 20 BOTOX ® Cosmetic grant recipients. Each... Read More

PICCOLO trial met its primary endpoint of objective response rate (ORR) Data from the study will be presented at a future medical meeting NORTH CHICAGO, Ill. , June 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE ® ) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα)... Read More

Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000 IRVINE, Calif. , June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOTOX ® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica ® . To mark this milestone anniversary, Allē Members who purchase SkinMedica ® products at a participating Allē Health Care Provider or SkinMedica.com from... Read More

The submission period is now open to individuals living with migraine for the new AbbVie Migraine Career Catalyst Award™ contest, awarding winners with a financial prize that they may decide to use to support their career and professional development goals As the only company with three treatment options designed to meet patient needs across the spectrum of migraine, AbbVie is dedicated to addressing the impact of migraine... Read More

ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM) The CERVINO Phase 3 trial will evaluate the efficacy, safety, and tolerability of ABBV-383 monotherapy compared with standard available therapies (SATs) in patients with r/r MM who have received at least two lines of prior therapy NORTH CHICAGO, Ill. , June 5, 2024 /PRNewswire/ --... Read More

First indications of RINVOQ (upadacitinib) for pediatric patients two years of age and older 1 RINVOQ is now approved for eight indications across immune-mediated inflammatory diseases 1 NORTH CHICAGO, Ill. , June 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that RINVOQ ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular... Read More

Join Allē Today to Start Sharing and Earning Rewards Refer a Friend by Allē Lets Consumers Earn up to $50 to Use Towards Allergan Aesthetics Products and Treatments IRVINE, Calif. , June 4, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the debut of Refer a Friend, a new offering from Allē , the Allergan Aesthetics Loyalty Rewards Program. Now, Allē Members can invite their friends... Read More

NORTH CHICAGO, Ill. , June 3, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D., senior vice... Read More

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC) 1,2 In both trials, the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including endoscopic improvement** and histologic-endoscopic mucosal improvement, † were... Read More

New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine neoplasms (NENs). Data from... Read More

Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill. , May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie.... Read More

AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD) Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI ® ) versus ustekinumab (STELARA ® ) in Crohn's disease include an economic analysis and oral presentation that assessed... Read More

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK , May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders.... Read More

QULIPTA is now the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent migraine across all frequencies, including episodic and chronic. Expanded indication provides an additional treatment option for those with chronic migraine whose frequent disabling attacks negatively impact performance of daily activities. Approval was based on a pivotal Phase 3 clinical trial that... Read More

NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D., senior vice president, chief... Read More

Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31 , a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $12.310 Billion , an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational Basis First-Quarter Global... Read More

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 16 1 LEVEL UP, a Phase 3b /4 head-to-head study, compared upadacitinib to dupilumab for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis who had inadequate response to systemic therapy or when use of... Read More

Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX ® Cosmetic, the JUVÉDERM ® Collection of Fillers, and Allē, the Allergan Aesthetics Loyalty Rewards Program IRVINE, Calif. , April 23, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX ® Cosmetic , the... Read More

Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ ® ; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid taper regimen 1 The safety profile in GCA was generally consistent with that in approved... Read More

Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48 weeks of open-label treatment Findings will be showcased in an oral presentation at the American Academy of Neurology (AAN)... Read More

From the makers of BOTOX ® Cosmetic, two new SkinMedica ® acne products help address skin blemishes and can be combined with in-office DiamondGlow ® IRVINE, Calif. , April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica ® by the makers of BOTOX ® Cosmetic. The SkinMedica ® Acne Clarifying Treatment and SkinMedica ® Pore Purifying Gel... Read More

NORTH CHICAGO, Ill. , April. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that... Read More

Offering $200 Off the First CoolSculpting® Treatment IRVINE, Calif. , April 3, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is announcing its second annual CoolMonth celebration featuring CoolSculpting® Elite. From April 1 through April 30, 2024 , consumers can access CoolSavings promotions to help accelerate their body contouring journey. Leveraging last year's success, which saw more than 62,000... Read More

Allergan Aesthetics is raising the conversation on patient safety and ethical standards As part of its established Aesthetics-Ethics program, this year's Anti-Age Medicine World Congress (AMWC) launches Moving the Needle on Ethics Book Thought-provoking articles and interviews with leading medical practitioners from around the world discuss the impact of ethical practices and aim to raise awareness and create discussion... Read More

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a... Read More

The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer (PROC) Data show that ELAHERE treatment resulted in an overall survival benefit and reduced the risk of cancer progression by 35% ELAHERE represents AbbVie's first approved solid tumor treatment following the... Read More

Two expert-led Allergan Medical Institute (AMI) symposia will explore a personalized approach to aesthetics, featuring live injection sessions with Dr Mauricio De Maio , Dr Mansi Mukherjee and Dr Steven Liew World class experts to convene on socially transformative aesthetic medicine at Science of Aging TM event Seventeen posters exhibiting new clinical data on toxins and fillers showcase the diverse Allergan Aesthetics... Read More

NORTH CHICAGO, Ill. , March 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D., senior vice president,... Read More

A total of 29 abstracts, including three late-breaking presentations, demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing science across a spectrum of immune-mediated dermatologic conditions and aesthetic indications NORTH CHICAGO, Ill. , March 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three... Read More

THE FIRST AND ONLY HYALURONIC ACID DERMAL FILLER APPROVED FOR THE IMPROVEMENT OF MODERATE TO SEVERE TEMPLE HOLLOWING 1 IRVINE, Calif. , March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM ® VOLUMA ® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21. 1 JUVÉDERM ® VOLUMA ® XC is the... Read More

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET ® to enter into clinical trials. WALTHAM, Mass. , March 5, 2024 /CNW/ -- Dragonfly Therapeutics, Inc. , a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a... Read More

Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France , Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA... Read More

NORTH CHICAGO, Ill. , Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D., senior vice president, chief... Read More

NEWPORT BEACH, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics , a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), has released topline results from Phase III on Healis’ lead compound, CKDB-501A. The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving... Read More

A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in patients with relapsed or refractory (R/R) follicular lymphoma (FL), demonstrating strong and durable treatment responses In November 2023 , the FDA granted this investigational indication a Breakthrough Therapy Designation (BTD) NORTH CHICAGO, Ill. , Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV)... Read More

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology AbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by Tentarix NORTH CHICAGO, Ill. and SAN DIEGO , Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Tentarix... Read More

FOR THE SECOND YEAR, BOTOX ® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY IRVINE, Calif. , Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX ® Cosmetic grant program supporting women entrepreneurs. BOTOX ® Cosmetic partnered with IFundWomen to launch the... Read More

Richard A. Gonzalez to retire as AbbVie CEO to become Executive Chairman Transition will occur on July 1, 2024 NORTH CHICAGO, Ill. , Feb. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael , AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr. Gonzalez, who has... Read More

A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie's commitment to produce a portfolio of products that aim to improve the lives of patients living with inflammatory bowel diseases (IBD) Oral data presentations include a new post-hoc analysis of clinical and endoscopic outcomes from the SEQUENCE trial comparing risankizumab (SKYRIZI ® ) versus ustekinumab, results from the... Read More

NORTH CHICAGO, Ill. , Feb. 15, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable May 15, 2024 , to stockholders of record at the close of business on April 15, 2024 . Since the company's inception in 2013, AbbVie has increased its dividend by more than 285 percent. AbbVie is a member of the S&P Dividend Aristocrats... Read More

Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's late-stage development programs for ELAHERE provide... Read More

VYALEV is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease (aPD) in Canada . Advanced Parkinson's disease patients now have a non-surgical treatment option that addresses an unmet need within this community. In clinical trials, patients taking VYALEV achieved the primary endpoint of a reduction in motor fluctuations and morning akinesia, as well as... Read More

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the option to explore the applicability of Calibr-Skaggs' sCAR-T platform in autoimmune diseases Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches LA JOLLA,... Read More

Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11 , a Decrease of 19.3 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to 2023 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $54.318 Billion , a Decrease of 6.4 Percent on a Reported Basis and 5.9 Percent on an Operational Basis Full-Year Global Net... Read More

New report incorporates in-depth interviews, industry research and social listening to understand the role of individuality in the world of aesthetics Report underpins ongoing commitment to aesthetics accessibility and inclusivity to achieve desired patient outcomes IRVINE, Calif. , Jan. 31, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie (NYSE: ABBV) company and a global leader in medical aesthetics treatments,... Read More

Expert-led symposium will explore key emerging themes in aesthetics, supported by injection session live from Allergan Aesthetics Center of Excellence in Italy New clinical data will be presented to support evolving Allergan Aesthetics portfolio 2024 marks 10 years of Allergan Medical Institute (AMI) and a decade of commitment to science and advanced education IRVINE, Calif. , Jan. 25, 2024 /PRNewswire/ -- Allergan... Read More

ALLĒ SOLIDIFIES ITS POSITIONING WITH SATISFACTION SCORES IN THE NINETY-SECOND PERCENTILE BASED ON CONSUMER SURVEY IRVINE, Calif. , Jan. 23, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program. The survey of Allē Members who have been treated in the past twelve... Read More

PRODUODOPA ® (foslevodopa/foscarbidopa) is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease PRODUODOPA demonstrated sustained improvements in "Off" time (when symptoms return between medication doses), "On" time (when symptoms are controlled) without dyskinesia (involuntary movement), and morning akinesia ("Off" time upon waking) NORTH CHICAGO, Ill.... Read More

Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at week 16 than those treated with placebo 1,2 Higher response rates were also observed in patients receiving lutikizumab 300 mg weekly or 300 mg every other week than those treated with placebo in the... Read More

Collaboration to leverage Umoja's VivoVec TM gene delivery platform and AbbVie's expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidates NORTH CHICAGO, Ill. and SEATTLE , Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop... Read More

NORTH CHICAGO, Ill. , Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2023 financial results on Friday, February 2, 2024 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later... Read More

NORTH CHICAGO, Ill. , Jan. 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D. senior vice president,... Read More

Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65 th American Society of Hematology (ASH) congress Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma NORTH CHICAGO, Ill. , Dec. 9, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced... Read More

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions Transaction valued at $45.00... Read More

Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation antibodies BigHat to receive $30 million upfront payment with potential for further milestone payments and royalties NORTH CHICAGO, Ill. and SAN MATEO, Calif. , Dec. 5, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and BigHat... Read More

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE ® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations ImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio,... Read More

LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression Data from the study will be presented at a future medical meeting and we will discuss with global health authorities the potential to... Read More

Updates are supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial NORTH CHICAGO, Ill. , Nov. 27, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed or refractory (R/R) follicular lymphoma (FL). The FDA... Read More

ALLĒ MEMBERS CAN CELEBRATE THE HOLIDAY ALL OF NOVEMBER IRVINE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), celebrated the fifth annual BOTOX ® Cosmetic Day like never before, achieving record-breaking numbers. November-to-date saw the highest number of BOTOX ® Cosmetic treatments in history. 1-2 The highest number of gift cards were sold in BOTOX ® Cosmetic Day history. 1-2... Read More

More patients treated with UBRELVY ® 100 mg during the prodrome avoided the development of moderate or severe headache within 24 hours post-dose vs. placebo in those who could identify prodrome symptoms that were reliably followed by headache 1 UBRELVY is the first and only acute treatment for migraine that has demonstrated data in the prodrome phase in a Phase 3, double-blind, placebo-controlled trial AbbVie is the only... Read More

Refreshed Look Spotlights Most Diverse Breast Implant Portfolio for a Customized Look IRVINE, Calif. , Nov. 8, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), embraces the immensely personal choice that patients experience when choosing breast surgery. The new Natrelle ® campaign, "For Every BODY,"... Read More

CELEBRATING THE FIFTH ANNUAL BOTOX ® COSMETIC DAY, NEW AND LOYAL ALLĒ MEMBERS BENEFIT FROM MORE EXCITING OFFERS IRVINE, Calif. , Nov. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating the fifth annual BOTOX ® Cosmetic Day on Wednesday, November 15 . To commemorate this milestone, the brand is expanding its offerings like never before. New and loyal members of Allē, the Allergan... Read More

Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95 , a Decrease of 19.4 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share elated to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $13.927 Billion , a Decrease of 6.0 Percent on a Reported Basis and 5.8 Percent on an Operational Basis Third-Quarter Global Net... Read More

All primary and secondary endpoints were met for both Phase 3 studies (M21-500 and M21-508). Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and short duration of effect within 2-3 weeks. If approved, BoNT/E will be the first neurotoxin of its kind available to patients. IRVINE, Calif. , Oct. 24,... Read More

Ongoing Support for Breast Cancer Patients Through Initiatives Focused on Education and Elevating Patient Voices IRVINE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Yesterday, on Breast Reconstruction Awareness Day (National BRA Day), Allergan Aesthetics, an AbbVie company (NYSE: ABBV), launched Reblossom , a coffee table book featuring a collection of patient stories and photographs that celebrates the resilience of breast... Read More

Approval is based on results from three Phase 3 clinical trials demonstrating RINVOQ achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment 1,2,3,4,5 Safety results were generally consistent with the known safety profile of RINVOQ, with no new safety risks observed 1-5,6,7,8,9 RINVOQ is the first JAK inhibitor indicated in both Crohn's disease and ulcerative... Read More

MONTREAL , Oct. 17, 2023 /CNW/ - AbbVie (NYSE: ABBV), today announced that EPKINLY ™ (epcoritamab injection/epcoritamab for injection) has received Health Canada authorization with conditions. It is the first and only subcutaneous (SC) T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL transformed from... Read More

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs 1 Risankizumab met both primary endpoints of non-inferiority for clinical remission a (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic remission b at week 48 versus ustekinumab 1 Risankizumab... Read More

At week 24, upadacitinib met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV) 1 At week 52, the percent reduction from baseline in F-VASI was numerically greater than results at week 24 for all upadacitinib doses 1,2 The safety profile was consistent with the known safety profile for... Read More

Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ ® (upadacitinib) in treating moderate to severe atopic dermatitis based on results across 140 weeks 1 Response rates for EASI 75 and vIGA-AD 0/1 (co-primary endpoints) and for EASI 90 and WP-NRS 0/1 at week 16 were sustained through week 140 among patients treated with RINVOQ 1 Safety results... Read More

Late-breaking data from a head-to-head study evaluating SKYRIZI ® (risankizumab) versus STELARA ® (ustekinumab) in moderate to severe Crohn's disease will be presented Analyses on clinical and endoscopic outcomes from AbbVie's maintenance trials for SKYRIZI ® (risankizumab) and RINVOQ ® (upadacitinib) in moderate to severe Crohn's disease and for RINVOQ in moderate to severe ulcerative colitis Primary efficacy and safety... Read More

Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease Activation of PINK1 remediates mitochondrial damage and restores mitochondrial function NORTH CHICAGO, Ill. , Oct. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of... Read More

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV), the Broad Institute of MIT and Harvard , and Calico Life Sciences today announced the publication in Nature of the discovery and preclinical data that demonstrate investigational ABBV-CLS-484 is a potential first-in-class, orally bioavailable, PTPN2/N1 phosphatase inhibitor that enhances anti-tumor immunity. The findings,... Read More

NORTH CHICAGO, Ill. , Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessible through AbbVie's Investor Relations website investors.abbvie.com . An archived edition of the session will be available later that day. About... Read More

Girls Inc. alumnae in New York , San Antonio and Central Alabama will participate in a virtual panel titled 'Equipping the New Generation of STEM Leaders' with leading women physicians sharing their career journeys including growth moments and challenges A social media campaign shares authentic stories and aspirations of girls entering the workforce IRVINE, Calif. , Oct. 3, 2023 /PRNewswire/ -- Today Allergan Aesthetics, an... Read More

CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone Results are being presented at the International Myeloma Society Annual Meeting in Athens, Greece AbbVie will discuss the data with health authorities in the near future to further understand the potential of venetoclax as a biomarker-driven therapy in multiple myeloma NORTH... Read More

TEPKINLY ® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy Conditional marketing authorization approval from the European Commission is supported by data from the pivotal Phase 1/2 EPCORE™ NHL-1 clinical trial TEPKINLY represents AbbVie's second approved... Read More

All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309). Results support onabotulinumtoxinA as a potential treatment option for moderate to severe platysma prominence. Data will be included as part of an upcoming U.S. Food and Drug Administration regulatory submission expected near the end of the year. If approved,... Read More

Online and mobile voting is open to the public now through September 27 to help determine this year's two Thriving Students 40 students living with cystic fibrosis (CF) received $3,000 scholarships earlier this year based on their academic excellence, creativity, and community involvement Two deserving students will be awarded scholarships totaling $25,000 each NORTH CHICAGO, Ill. , Sept. 13, 2023 /PRNewswire/ -- AbbVie... Read More

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs 1 Risankizumab met both primary endpoints of non-inferiority for clinical remission (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic... Read More

NORTH CHICAGO, Ill. , Sept. 8, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable November 15, 2023 , to stockholders of record at the close of business on October 13, 2023 . Since the company's inception in 2013, AbbVie has increased its dividend by 270 percent. AbbVie is a member of the S&P Dividend Aristocrats... Read More

GET TO KNOW THE WOMEN-OWNED BUSINESSES RECEIVING GRANTS AND CONTRIBUTE TO THEIR SUCCESS, FURTHER CLOSING THE "CONFIDENCE GAP" IRVINE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the next chapter of the BOTOX ® Cosmetic and IFundWomen grant program with the launch of crowdfunding campaigns for the women entrepreneurs. The brand recently announced the recipients... Read More

NORTH CHICAGO, Ill. , Sept. 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 . Robert A. Michael , president and chief operating officer, Scott Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , senior vice president,... Read More

At day 30, approximately 90% of all study patients were satisfied with treatment resulting in a natural look and more than 80% of all study patients were satisfied with natural-looking outcomes throughout the 12-month study period for the temporary improvement in the appearance of their moderate to severe upper facial lines 1 At day 30, more than half of patients experienced a notable difference in self-perceived appearance... Read More

Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted Mayo Score) and key secondary endpoints as an induction and maintenance treatment 1,2 Safety results were generally consistent with the known safety profile of risankizumab, with no new safety risks observed 1,2 Risankizumab is an IL-23 inhibitor being evaluated as a treatment... Read More